Carregant...
Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
As a bisphosphonate, minodronate (MIN) is one of the strongest inhibitors of bone resorption. However, there have been no reports directly comparing the antiresorptive effects of monthly MIN with those of monthly risedronate (RIS). We enrolled 30 cases of osteoporosis (OP; 16 in the MIN group [mean...
Guardat en:
| Publicat a: | Osteoporos Sarcopenia |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Korean Society of Osteoporosis
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6372746/ https://ncbi.nlm.nih.gov/pubmed/30775483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.afos.2016.07.002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|